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BACKGROUND
Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue 
neoplasms that can arise in any anatomical location and infiltrate the mesentery, 
neurovascular structures, and visceral organs. There is no standard of care.
METHODS
In this double-blind, phase 3 trial, we randomly assigned 87 patients with progres-
sive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-
mg tablet once daily) or matching placebo. Crossover to the sorafenib group was 
permitted for patients in the placebo group who had disease progression. The 
primary end point was investigator-assessed progression-free survival; rates of 
objective response and adverse events were also evaluated.
RESULTS
With a median follow-up of 27.2 months, the 2-year progression-free survival rate 
was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% 
(95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 
0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate 
was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in 
the placebo group. The median time to an objective response among patients who 
had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib 
group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group. 
The objective responses are ongoing. Among patients who received sorafenib, the 
most frequently reported adverse events were grade 1 or 2 events of rash (73%), 
fatigue (67%), hypertension (55%), and diarrhea (51%).
CONCLUSIONS
Among patients with progressive, refractory, or symptomatic desmoid tumors, 
sorafenib significantly prolonged progression-free survival and induced durable 
responses. (Funded by the National Cancer Institute and others; ClinicalTrials.gov 
number, NCT02066181.)
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Desmoid tumors (also called aggres-sive fibromatosis) are rare, locally aggres-sive neoplasms that arise from connective 
tissues.1 The annual incidence of the condition is 
estimated to be 1000 patients in the United 
States, and the prevalence may be higher. Des-
moid tumors typically affect young adults in 
their 20s and 30s, but they can occur in children, 
adolescents, and older adults. Most desmoid tu-
mors are sporadic (>90%) and harbor CTNBB1 
mutations; a minority of tumors are associated 
with germline APC mutations and Gardner’s 
syndrome.2-4 Common primary sites affected by 
these tumors include the abdominal wall, mesen-
tery, and neurovascular bundle of the extremi-
ties. Desmoid tumors do not metastasize and 
pose a low risk of death (except in Gardner’s 
syndrome), but they confer substantial complica-
tions. Patients may be asymptomatic or may 
present with severe pain, swelling, deformity, 
loss of range of motion, bowel obstruction or 
perforation, or compromise of vital organs.5 Ad-
ditional associated complications in young adults 
include long-term opioid use, social isolation, 
insomnia, anxiety, depression, and interruption 
of education and employment.6
Although a number of agents have activity 
against desmoid tumors, no accepted standard 
of care exists for systemic treatment of the tu-
mors.7 Beyond a few prospective trials, most rel-
evant clinical data have been derived from case 
series and retrospective analyses. Interpretation 
of the data is challenging, given the unpredict-
able natural history of the condition. Desmoid 
tumors can show rapid growth followed by peri-
ods of stabilization, spontaneous regression, or 
subsequent growth phases.2 Spontaneous regres-
sion is reported in up to 20% of patients.8 An 
up-front watch-and-wait strategy is increasingly 
advocated for many patients.9-11 Surgery has been 
the standard of care for primary treatment, but 
the risk of local recurrence remains unacceptably 
high (>40%). Local (radiation therapy) or systemic 
treatments are usually indicated in patients who 
have disease-related symptoms or progressive 
disease. Systemic treatment options include hor-
monal blockade, cytotoxic chemotherapy, and ty-
rosine kinase inhibitors; the response rates asso-
ciated with these treatments vary (0 to 40%).12-19 
For example, in small prospective studies, imati-
nib has been found to have limited activity (6 to 
11%), and no predictive biomarkers of benefit 
were found.20
In a retrospective analysis, sorafenib, an oral 
multitargeted receptor tyrosine kinase inhibitor, 
at a starting dose of 400 mg once daily was 
shown to have acceptable safety and was associ-
ated with a response rate of 25%, as evaluated 
with Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1, as well as with improve-
ments in quality of life.21 The retrospective study 
also highlighted that RECIST may underestimate 
efficacy and that a better criterion may be mag-
netic resonance imaging (MRI) T2-weighted sig-
nal intensity, an imaging biomarker that signi-
fies a biologic transformation from a cellular 
tumor to a collagenous scar.22 This hypothesis 
prompted us to conduct a randomized, double-
blind, placebo-controlled, phase 3 trial to evalu-
ate the safety and efficacy of sorafenib in the 
treatment of desmoid tumors.
Me thods
Patients
We enrolled patients 18 years of age or older with 
a histologically documented desmoid tumor 
(aggressive fibromatosis) if they had measurable 
disease and radiographic progression (of ≥10%) 
in maximum unidimensional measurement with-
in the previous 6 months, recurrent or primary 
disease that was deemed inoperable or as requir-
ing extensive surgery, or symptomatic disease. 
An additional entry criterion was an absence of 
previous sorafenib exposure; no minimum or 
maximum number of previous systemic treat-
ments was stipulated. The complete entry and 
crossover eligibility criteria, including baseline 
laboratory values, are provided in the protocol, 
available with the full text of this article at 
NEJM.org.
Trial Oversight
The trial was conducted in accordance with the 
Declaration of Helsinki, Good Clinical Practice 
guidelines, and federal and local policy on bio-
ethics and human biologic specimens. Each par-
ticipating institution obtained approval from a 
local or central institutional review board. All 
the patients signed informed consent forms in 
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accordance with federal and institutional guide-
lines. The trial was designed by the first author 
and monitored by the Alliance Data and Safety 
Monitoring Board for the evaluation of safety 
and the primary end point.
This trial was funded by the National Cancer 
Institute and was conducted by the Alliance 
Clinical Trials in Oncology Group and the Na-
tional Clinical Trials Network (Table S1 in the 
Supplementary Appendix, available at NEJM.org). 
Sorafenib was provided by the National Cancer 
Institute through a research collaboration with 
Bayer Pharmaceuticals.
All the data were collected, subjected to 
quality-assurance measures, and analyzed by the 
Alliance Statistics and Data Center. Archival tu-
mor tissue for central pathological review, biopsy 
specimens (optional), and MRI scans were de-
identified with regard to patient health informa-
tion and, after completion of quality-assurance 
measures, were sent for central pathological re-
view and correlative studies. The authors attest 
to the accuracy and completeness of the data 
and for the adherence of the trial to the proto-
col. The first draft of the manuscript was written 
by the principal investigators (the first and sec-
ond authors); all the authors reviewed the manu-
script. No one who is not an author contributed 
to the writing of the manuscript.
Trial Design and Treatment
In this investigator-initiated, double-blind, placebo-
controlled, phase 3 trial, patients were randomly 
assigned (in a 2:1 ratio) to receive either sorafenib 
(at a starting dose of 400 mg once daily) or pla-
cebo. Desmoid tumors were imaged by means of 
computed tomography (CT) or MRI at baseline 
and every 8 weeks. Efficacy was assessed at local 
institutions with the use of RECIST, version 1.1.23 
Administration of sorafenib or placebo continued 
until disease progression, unacceptable side ef-
fects, or withdrawal of consent. At disease pro-
gression, the patients were told whether they had 
been receiving sorafenib or placebo, and those 
who had been receiving placebo were eligible to 
cross over to the sorafenib group if they still met 
the trial entry criteria. Dose interruptions (of up 
to 28 days) and one dose reduction (to 200 mg 
once daily) were permitted and described in the 
trial protocol.
End Points and Assessments
The primary end point was progression-free sur-
vival, as determined by the treating physicians in 
accordance with RECIST, version 1.1. This end 
point was defined as the time from randomiza-
tion to progressive disease (radiographic, clini-
cal, or both) or death, and data were censored at 
the most recent disease assessment. A modifica-
tion of the traditional intention-to-treat principle 
was used for the analysis of the primary end 
point, in which patients with an incorrect histo-
logic diagnosis were excluded. The secondary 
end points were toxic effects, the rate of radio-
graphic response, and overall survival. Ineligible 
patients who received a trial agent were included 
in the assessment of toxic effects, in which the 
Common Terminology Criteria for Adverse Events 
(CTCAE), version 4.03, were used.
At enrollment, patients were given the option of 
consenting to undergo tumor biopsies and surveys 
with patient-reported outcome questionnaires at 
baseline and while taking the trial regimen. Ex-
ploratory end points included assessment of pain 
with the use of the Brief Pain Inventory and assess-
ment of 11 side effects with the patient-reported 
outcomes version of the CTCAE (PRO-CTCAE, 
version 1.0) before crossover. Exploratory imag-
ing end points included a comparison of RECIST 
measurements with total tumor volume and MRI 
T2-weighted signal intensity in patients.
Statistical Analysis
We calculated that a sample of 75 patients, each 
with 12 months of follow-up, would provide 90% 
power at a one-sided significance level of 0.025 
(with the use of a stratified log-rank test) to 
detect a median progression-free survival that 
was 9 months longer with sorafenib than with 
placebo (with an expected median progression-
free survival of 6 months among patients receiv-
ing placebo) and a hazard ratio of 0.4 for pro-
gression or death in the sorefenib group relative 
to the placebo group. Enrollment was estimated 
at 4 patients per month, for an anticipated dura-
tion of 21 months to complete enrollment. The 
final analysis was to occur at the time that 52 
patients had had disease progression or had died. 
Sorafenib was to be declared as superior with 
regard to progression-free survival if the one-
sided P value associated with the stratified 
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log-rank test statistic was less than 0.025. A 
preplanned, nonbinding futility analysis was 
performed when 24 (45%) of the 52 required 
events had been observed.
Kaplan–Meier methods and Cox proportional-
hazards modeling were used to estimate the dis-
tributions of time-to-event variables and hazard 
ratios (including confidence intervals), respec-
tively, accounting for stratification factors.24,25 
Summary statistics, frequency tables, and para-
metric and nonparametric statistical tests were 
used, as applicable. The maximum PRO-CTCAE 
score for each item during the intervention with 
accounting for baseline PRO-CTCAE score was 
tabulated for each trial group, and the differ-
ence between the groups in the proportion of 
patients with a score of at least 1 and, sepa-
rately, with a score of at least 3 was computed 
with exact 95% confidence intervals.26 All P val-
ues and confidence intervals are two-sided and 
unadjusted for multiplicity. All the observed 
data were included in the analysis without im-
putation for missing data. All the analyses were 
performed with the use of SAS software, ver-
sion 9.4 (SAS Institute). The data-lock date was 
January 31, 2018.
Figure 1. Randomization and Follow-up among the Patients in the Trial.
87 Patients underwent randomization
37 Were assigned to receive placebo
30 Consented to provide data on
patient-reported outcomes
50 Were assigned to receive sorafenib
37 Consented to provide data on
patient-reported outcomes
1 Withdrew before initiation
of trial regimen
1 Withdrew before initiation
of trial regimen
36 Received placebo and were included
in safety analysis
49 Received sorafenib and were included
in safety analysis
1 Was found to be ineligible
after starting treatment owing
to incorrect histologic diagnosis
36 Were included in efficacy and safety
analyses
35 Were included in primary and secondary
outcome analyses
28 Were included in analysis of patient-
reported outcomes
49 Were included in primary and secondary
outcome analysis
36 Were included in analysis of patient-
reported outcomes
36 Discontinued placebo
23 Had disease progression
1 Had other, complicating
disease
1 Withdrew after starting
regimen
1 Had other reasons
10 Had trial-group assignment
unmasked
30 Discontinued sorafenib
11 Withdrew after starting
regimen
10 Had adverse events
5 Had disease progression 
3 Had other reasons
1 Underwent alternative
therapy
0 Were receiving placebo at data lock 31 Were receiving sorafenib at data lock
19 Were receiving initially assigned regimen
12 Crossed over from placebo
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R esult s
Patients, Enrollment, and Treatment
From March 21, 2014, to January 6, 2016, a total 
of 87 patients were enrolled across 24 sites; 50 
patients were randomly assigned to the sorafenib 
group and 37 to the placebo group (Fig. 1). A 
systems computer algorithm error was detected 
after 70 patients (38 in the sorafenib group and 
32 in the placebo group) had been enrolled. The 
randomization ratio was approximately 1.6 to 
1.7:1 (sorafenib:placebo) instead of the prespeci-
fied 2:1 ratio. This error was shared with the 
data and safety monitoring board, institutional 
review boards, treating physicians, and patients 
(in October 2015), with correction for the re-
mainder of enrollment.
The characteristics of the patients at baseline 
were well balanced between the two trial groups 
(Table 1).27 A larger percentage of female than 
male patients were enrolled (69%), and the me-
dian age of the patients was 37 years (interquar-
tile range, 28 to 50), findings consistent with the 
natural history of desmoid tumors; 80% of the 
patients reported their race as white. The median 
dose of sorafenib that was administered across 
the entire trial was 400 mg daily. Dose interrup-
tions occurred in 65% of the patients in the 
sorafenib group (32 of 49) and 34% of the pa-
tients in the placebo group (12 of 35), and dose 
reductions due to toxic effects occurred in 31% 
(15 of 49) and 11% (4 of 35), respectively. At data 
cutoff, 19 patients (39%) who had initially been 
assigned to the sorafenib group continued to 
take the drug. At the time of the interim analy-
sis, the data and safety monitoring board also 
requested an efficacy analysis, and subsequently 
the trial was halted and unblinded.
Efficacy
Of the 87 patients who underwent randomiza-
tion, 84 (97%) were included in the analysis of 
primary and secondary end points, with a me-
dian follow-up of 27.2 months (interquartile 
range, 22.0 to 31.7) among the 83 surviving 
patients. Although the median progression-free 
survival has not yet been reached, the estimates 
of the progression-free survival rates at 1 year 
were 89% (95% confidence interval [CI], 80 to 
99) in the sorafenib group and 46% (95% CI, 32 
to 67) in the placebo group, and the estimates 
at 2 years were 81% (95% CI, 69 to 96) and 36% 
(95% CI, 22 to 57), respectively. The results for 
progression-free survival favored sorafenib, with 
an 87% lower risk of progression or death in the 
sorafenib group than in the placebo group (haz-
ard ratio for disease progression or death, 0.13; 
95% CI, 0.05 to 0.31; P<0.001) (Fig. 2). Overall, 
33% of the patients in the trial (28 of 84) had 
disease progression: 12% of the patients (6 of 49) 
in the sorafenib group and 63% of the patients 
(22 of 35) in the placebo group. Clinical deterio-
ration in the absence of radiographic evidence 
was the sole indicator of progression in 11 of 
the 28 patients with progression (39%; 9 patients 
in the placebo group and 2 in the sorafenib 
group).
The overall rate of objective response was 
33% (95% CI, 20 to 48) in the sorafenib group 
(16 patients [1 with a complete response and 
15 with partial responses] of 49) and 20% (95% 
CI, 8 to 37) in the placebo group (7 patients 
[all of whom had a partial response] of 35) 
(Fig. 3A, and Fig. S1 in the Supplementary Ap-
pendix). The mean best percentage change in 
the sum of the target lesions (RECIST) was 
−26% (range, −100 to 7) in the sorafenib group 
and −12% (range, −85 to 32) in the placebo 
group. The median time to a RECIST-defined 
response among patients who had a response 
was 9.6 months (interquartile range, 6.6 to 16.7) 
in the sorafenib group and 13.3 months (inter-
quartile range, 11.2 to 31.1) in the placebo 
group (Fig. 3B). The earliest RECIST-defined 
partial response occurred at 2.2 months in sora-
fenib group and at 8.8 months in the placebo 
group.
In the exploratory imaging analysis, 498 MRI 
scans were obtained from 55 patients. We select-
ed a training set of 11 patients who were treated 
at a single institution (Memorial Sloan Kettering 
Cancer Center), and we analyzed 167 MRI scans 
for changes in tumor dimension (according to 
RECIST) and compared this value with the 
changes in total tumor volume and T2-weighted 
signal intensity. As shown in Figure S2 in the 
Supplementary Appendix, changes in T2-weighted 
signal intensity and volumetric measurements 
may be better measures of treatment effect 
than RECIST. This is particularly evident when 
the best response according to RECIST is stable 
disease.
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Median age (range) — yr 37 (21–67) 37 (18–72)
Female sex — no. (%) 26 (70) 34 (68)
ECOG performance-status score — no. (%)†
0 22 (59) 35 (70)
1 15 (41) 15 (30)
Median sum of target lesions at randomization (range) — cm 7.6 (2.6–26.5) 8.4 (1.2–19.3)
BPI worst pain score at randomization — no. (%)‡§
0–2 14 (38) 17 (34)
3–6 14 (38) 21 (42)
7–10 9 (24) 12 (24)
Intraabdominal disease — no. (%)‡ 16 (43) 16 (32)
Primary tumor site — no. (%)
Abdominal 16 (43) 14 (28)
Extraabdominal 18 (49) 32 (64)
Both abdominal and extraabdominal 3 (8) 4 (8)
Previous radiation therapy — no. (%) 3 (8) 6 (12)
Previous systemic therapy — no. (%) 15 (41) 18 (36)
Previous surgical resection — no. (%) 18 (49) 23 (46)
Disease status — no./total no. (%)
Newly diagnosed 19/37 (51) 26/48 (54)
Recurrent 18/37 (49) 22/48 (46)
Trial inclusion criteria — no. (%)¶
Disease determined to be unresectable or to require surgery with 
 unacceptably high associated morbidity
28 (76) 44 (88)
Progression detected by radiographic imaging within 6 months  
before randomization
16 (43) 19 (38)
Symptomatic disease with BPI worst pain score ≥3 and consideration  
of pain narcotic introduction or escalation‖
11 (30) 16 (32)
*  The intention-to-treat population included all patients who underwent randomization with the exception of those who 
were identified after randomization as not having a desmoid tumor and those who did not initiate the trial regimen and 
did not undergo further follow-up. Randomization was based on a dynamic allocation algorithm developed and imple-
mented by the Alliance Statistics and Data Center. An error in the assignment of the trial regimen was detected and recti-
fied after 70 patients (38 in the sorafenib group and 32 in the placebo group) had been enrolled. The program deriving 
the assignments of trial regimens incorrectly recognized a patient’s crossover regimen as the initial assigned regimen 
when balancing for new enrollments. Randomization was stratified according to anatomical location and level of pain 
at the time of randomization, assessed with the use of the worst pain item of the Brief Pain Inventory (BPI) completed 
by the patient within 28 days before randomization. There were no significant differences (P<0.05) between the groups 
in any of the characteristics at the time of randomization. Percentages may not total 100 because of rounding.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher 
scores indicating greater disability; a score of 5 indicates death.
‡  The characteristic was a stratification factor at randomization.
§  The BPI worst pain question was “Please rate your pain by circling the one number that best describes your pain at its 
WORST in the last 24 hours: 0 (no pain)–10 (pain as bad as you can imagine).”
¶  Patients had to meet at least one of these three criteria to be eligible for participation in the trial.
‖  Consideration of pain narcotic introduction or escalation was defined as an inability to control pain with nonsteroidal 
antiinflammatory drugs and consideration of the addition of narcotics or a more than 30% increase in the current use 
of narcotics or the addition of a new opioid narcotic.
Table 1. Demographic and Clinical Characteristics of the Patients at Randomization.*
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Safety
A total of 85 patients (49 in the sorafenib group 
and 36 in the placebo group) were included in 
the assessment of safety with the use of CTCAE, 
version 4.0. A summary of the most common 
adverse events is provided in Table 2. Adverse 
events led to a significantly higher rate of dis-
continuation of the trial regimen in the sorafenib 
group than in the placebo group (20% vs. no 
patients). The most common reason for dose 
reduction in the sorafenib group was skin disor-
ders. Grade 3 adverse events that were attributed 
to the trial regimen by the investigators oc-
curred in 29% of patients in the sorafenib group 
and 14% of patients in the placebo group. Grade 4 
events that were associated with sorafenib in-
cluded thrombocytopenia (2%) and anemia 
(2%). One patient in the sorafenib group died 
from disease-related bowel perforation. A list 
of the side effects reported by the patients with 
the use of PRO-CTCAE is provided in Table S4 
and Figure S3 in the Supplementary Appendix. 
The proportions of patients with nausea, diar-
rhea, rash, and hand–foot syndrome were high-
er in the sorafenib group than in the placebo 
group.
Crossover
In the placebo group, 27 patients met the eligi-
bility criteria for open-label sorafenib treatment 
(20 at disease progression and 7 when the data 
and safety monitoring board released results), 
and 12 patients continue to take sorafenib; how-
ever, the data remain immature. The toxic ef-
fects among the patients receiving open-label 
sorafenib were similar to those among the pa-
tients who were initially randomly assigned to 
receive sorafenib and are listed in Table S7 in the 
Supplementary Appendix.
Discussion
This randomized trial provides data on the ef-
ficacy of sorafenib in patients with progressive or 
symptomatic desmoid tumors. Other agents that 
are used to treat these tumors include anthracy-
clines (e.g., pegylated liposomal doxorubicin), 
vinca alkaloids, and pazopanib. On the basis of 
the predictable toxic-effects profile and substan-
tial progression-free survival advantage conferred 
by sorafenib, the drug has antitumor activity as 
first-line therapy or as subsequent therapy for 
desmoid tumors.
For a locally infiltrative tumor, the prevention 
of further worsening or compromise of vital 
structures is a clinically meaningful end point. 
In that context, among patients with progres-
sive, symptomatic, or recurrent desmoid tumors, 
the rate of progression-free survival with sora-
fenib at 1 year was 89%. Patients treated with 
sorafenib had an 87% lower risk of disease pro-
gression or death than those who received place-
bo. To balance the efficacy of the drug against the 
long-term drug-related toxic effects, we chose a 
starting dose of sorafenib (one 400-mg tablet 
daily) that was lower than the dose used in 
other types of cancer and permitted dose inter-
ruptions and reductions.5 The modest toxicity 
of sorafenib was confirmed in both clinician-
reported and patient-reported assessments of ad-
verse events. Consistent with previous literature, 
Figure 2. Kaplan–Meier Estimates of the Duration of Progression-free Survival 
at the Time of the Last Assessment.
Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, were 
used by the investigators to identify disease progression. Data from patients 
who did not have progression or who had died were censored and marked 
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the rates of adverse events that were based on 
clinician reporting were substantially lower than 
those that were based on patient reporting.28
Many of these differences were due to the ability 
to detect more lower-grade mild-to-moderate 
side effects with the use of the patient-reported 
Figure 3. Tumor Responses and Clinical Outcomes.
Panel A shows waterfall plots of percentage changes from baseline in tumor size as assessed by investigators according to RECIST, ver-
sion 1.1. Each bar represents one patient. Horizontal dashed lines indicate the changes in tumor size that would represent a partial re-
sponse (30% decrease) or progressive disease (20% increase). One patient in the sorafenib group had a complete response, defined as 
total disappearance of tumor. Panel B shows swimmer plots of the duration of response and clinical outcomes among patients during 
the trial. “Progression nonmeasure” denotes clinical progression without radiographic progression (20% growth). One patient in the 
sorafenib group died from disease-related intestinal perforation. Duration of response was calculated as the time between the first ob-
jective response and disease progression; data from patients with ongoing responses were censored at the most recent disease assess-
ment. Time to response during the time of the blinded trial intervention was calculated from the start of the intervention to the date of 
the first objective response or to the most recent disease assessment (for patients without a response). Time to progression was the 
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Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4
number of patients (percent)
Any adverse event 26 (53) 23 (47) 25 (69) 9 (25)
Events during receipt of trial regimen with incidence 
≥10%†
Palmar–plantar erythrodysesthesia syndrome 34 (69) 1 (2) 8 (22) 0
Rash
Any rash or skin disorder 36 (73) 7 (14) 15 (42) 0
Papulopustular 24 (49) 6 (12) 6 (17) 0
Acneiform 6 (12) 0 0 0
Maculopapular 7 (14) 0 1 (3) 0
Skin or subcutaneous tissue disorders — 
other‡
7 (14) 1 (2) 5 (14) 0
Pruritus 7 (14) 0 0 0
Fatigue 33 (67) 3 (6) 22 (61) 1 (3)
Hypertension 27 (55) 4 (8) 14 (39) 0
Diarrhea 25 (51) 0 12 (33) 0
Nausea 24 (49) 0 14 (39) 1 (3)
Myalgia 18 (37) 1 (2) 12 (33) 0
Alopecia 18 (37) 0 3 (8) 0
Arthralgia 17 (35) 1 (2) 9 (25) 0
Abdominal pain 15 (31) 1 (2) 9 (25) 4 (11)
Anorexia 15 (31) 0 9 (25) 0
Constipation 11 (22) 0 4 (11) 0
Oral mucositis 11 (22) 0 6 (17) 0
Vomiting 10 (20) 1 (2) 6 (17) 2 (6)
Anemia 8 (16) 1 (2) 2 (6) 1 (3)
Increase in alanine aminotransferase level 7 (14) 0 4 (11) 0
Decrease in platelet count 6 (12) 2 (4) 1 (3) 0
Hyperglycemia 6 (12) 1 (2) 3 (8) 0
Peripheral sensory neuropathy 6 (12) 0 1 (3) 0
Increase in aspartate aminotransferase level 5 (10) 1 (2) 3 (8) 0
Increase in blood bilirubin level 5 (10) 0 3 (8) 1 (3)
Decrease in neutrophil count 5 (10) 0 2 (6) 0
Dry skin 5 (10) 0 1 (3) 0
Headache 4 (8) 0 6 (17) 0
Decrease in white-cell count 3 (6) 0 6 (17) 0
Musculoskeletal connective-tissue disorders — 
other§
3 (6) 0 4 (11) 0
*  Events that occurred while the patient was taking the initially assigned trial regimen (before crossover) are shown. 
Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. 
The events reported reflect the maximum severity in each category for a given patient during the treatment period; mul-
tiple occurrences of the same event in a single patient were counted once, at the highest grade at which it occurred. All 
85 patients were included in the assessment of safety.
†  Events that had an incidence of 10% or higher in either trial group are shown. One patient in the sorafenib group died 
from disease-related bowel perforation (not shown in this table) that was judged by the investigators not to have been 
related to the drug; no other grade 5 events occurred.
‡  Events in this category included callus, swelling, plantar wart, hidradenitis supportiva, and pain.
§  Events in this category included pain and cramping.
Table 2. Incidence of Adverse Events of Any Cause According to Initially Assigned Trial Regimen.*
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PRO-CTCAE. Accordingly, we surmised that the 
high rate of withdrawal from the trial due to 
adverse events (20%) suggests that even greater 
dose flexibility may be necessary to balance tox-
icity and benefit.
This trial highlights the importance of ran-
domization in the conduct of clinical trials. 
Spontaneous regression was once considered to 
be anecdotal and rare (occurring in <5% of pa-
tients), but more recent retrospective, nonrandom-
ized studies have shown higher rates of sponta-
neous remission.8,9 Our prospective trial, in which 
desmoid tumors in patients who were taking 
placebo were evaluated, provides evidence in sup-
port of an initial period of observation in pa-
tients with newly diagnosed desmoid tumors, 
given that 20% of the patients in the placebo 
group had disease regression. In this trial, late 
responses were observed in the sorafenib group, 
and response rates may increase with further 
data maturation.
A final important clinical issue to note re-
gards the feasibility and challenges of conduct-
ing clinical trials in very rare cancers. Rare 
cancers are defined as those with an incidence 
of less than 15 cases per 100,000 persons per 
year. Although individually uncommon, rare can-
cers account for 25% of all cancers and are as-
sociated with poor survival.29,30 The main chal-
lenges in the design and execution of this phase 3 
trial were the incidence of the cancer (0.3 cases 
per 100,000 persons per year), the lack of con-
sensus on the standard of care, the lack of pre-
dictive biomarkers for the selection of patients, 
and the lack of validated, desmoid-specific pa-
tient-reported outcome measures. The unreliabil-
ity of historical data on treatment and natural 
history (e.g., the rate of spontaneous regression) 
was an additional design challenge. All potential 
trial designs (e.g., frequentist or Bayesian) should 
be considered on the basis of not only their sta-
tistical properties but also their feasibility with 
regard to late events or logistic support for real-
time data entry. The trial conducted was an inter-
national collaboration among U.S. and Canadian 
National Cancer Institutes, cooperative research 
groups, patient advocacy groups, and physician 
outreach groups, an endeavor that facilitated the 
enrollment of 87 patients in 17 months.29,31
A limitation of this trial is that it was not 
designed to directly compare the primary or 
secondary end points with meaningful improve-
ments in pain palliation, functionality, or qual-
ity of life. The use of pain-palliation question-
naires was optional, and limited results were 
available. In our exploratory analysis, we were 
unable to use the Brief Pain Inventory to discern 
any difference between the groups (data not 
shown), contrary to previous reports. Symptoms 
that affect patients with desmoid tumors are 
wide-ranging, and since this trial was conducted, 
a prospective, desmoid tumor–specific, patient-
reported outcome tool has been developed for 
future trials.6 Beyond the traditional end points 
that are used in clinical trials, incorporating an 
evaluation of the patient experience is critical.32
The ability to use RECIST-defined responses 
to correlate with treatment effect and survival 
among patients with solid tumors is debated. 
Data from our exploratory analysis suggested 
that there is anatomical and mathematical dis-
cordance among assessments that are based on 
unidimensional measurement (RECIST), tumor 
volume, and T2-weighted signal intensity; there-
fore, RECIST — the current regulatory metric 
— may underestimate treatment effects. This 
phenomenon is observed in other sarcomas, such 
as tenosynovial giant-cell tumors and gastroin-
testinal stromal tumors, in which tumor volume 
and density are better predictors of treatment 
effect than RECIST measurements.33,34 Similarly, 
data have suggested that tumor volume or MRI 
T2-weighted signal intensity — namely, a shift 
from a cellular mass to a collagenous scar — 
may be additional imaging biomarkers that can 
potentially be used to assess treatment effects 
on desmoid tumors.22,35 The appropriate dura-
tion of sorafenib treatment and its cost and 
benefit relative to those of existing therapies 
remain unknown. Finally, the mechanism of 
action of sorafenib in desmoid tumors36 is not 
known. Investigations into changes in gene 
expression and protein phosphorylation of re-
ceptor tyrosine kinases (e.g., platelet-derived 
growth factor receptor, fibroblast growth factor 
receptor, and transforming growth factor beta 
receptor) and the Wnt signaling pathway are 
ongoing in the 25 sets of paired biopsy speci-
mens we obtained.
In conclusion, in this trial, therapy with sora-
fenib appeared to be effective in slowing disease 
progression in patients with desmoid tumors.
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